|
| |
| | Guidance for Industry: Population Pharmacokinetics |
 | | The full pharmacokinetic screen (experimental population pharmacokinetic) study should be designed to explore the relationship between the pharmacokinetics of a drug and demographic/pathophysiological features of the target population (with its subgroups) for which the drug is being developed. | | | The approach uses individual pharmacokinetic data of the observational (experimental) type, which are unbalanced and fragmentary, in addition to or instead of conventional pharmacokinetic data from traditional pharmacokinetic studies characterized by rigid and extensive design. | | | Population pharmacokinetic analysis is useful for looking at influences of pathophysiological conditions on parameters of a model with a well-established structure. |
|
http://www.fda.gov/cder/guidance/1852pk.htm
(9157 words)
|
|
| |
| | Section 1 - Review of Pharmacokinetic Concepts |
| | Pharmacokinetics is the study of the time course of the drug concentration in the body, i.e., "what the body does to the drug". | | | Clinical pharmacokinetics deals with the application of pharmacokinetic principles to the safe and effective therapeutic management of drug dosage in an individual patient. | | | Pharmacodynamics is the study of the relationship of drug concentration to pharmacologic effects, i.e., "what the drug does to the body". |
|
http://www.rxkinetics.com/pktutorial/1_1.html
(368 words)
|
|
| |
| | Pharmacokinetics |
| | Application of biopharmaceutics and pharmacokinetics to patient care and drug therapy. |
|
http://www.pharmacy.ualberta.ca/pharm415
(19 words)
|
|
| |
| | Pharmacokinetics in the Child |
| | These developments have enhanced the ability to conduct comprehensive pharmacokinetic studies to define the population pharmacokinetics of drugs in the pediatric population and clinical monitoring studies to define the optimal use of measured drug concentrations in serum or plasma and to individualize drug therapy. | | | As a result, pharmacokinetic studies must often be performed on sick children under treatment when a variety of logistical factors (limited access to blood samples, limited volume of blood samples, etc.) as well as ethical concerns make performance of such studies difficult. | | | Pharmacokinetic studies have made many significant contributions to rational therapeutics in children. |
|
http://www.ehponline.org/members/1994/Suppl-11/crom-full.html
(4836 words)
|
|
| |
| | Influence of Fluoxetine on Olanzapine Pharmacokinetics |
| | Because CYP2D6 is one of the pathways of olanzapine metabolism, and various metabolic pathways for fluoxetine may compete with those for olanzapine, fluoxetine might influence the pharmacokinetic profile of olanzapine. | | | For all pharmacokinetic variables except tmax, treatment groups were compared using a repeated-measures analysis of variance (ANOVA). | | | The research summarized therein identifies CYP1A2 and glucuronyl transferase (UDPGT) as the primary metabolic pathways and shows that CYP2D6 is only a minor metabolic pathway. |
|
http://www.aapsj.org/view.asp?art=ps040211
(2402 words)
|
|
| |
| | Pharmacokinetics in the Infant |
| | Developmental pharmacokinetics of mezlocillin in 4 newborn infants. | | | Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. | | | However, quantitation of clinical effects and pharmacodynamic response as modified by development and disease are areas that have lagged behind description of pharmacokinetics in this age group (10). |
|
http://www.ehponline.org/members/1994/Suppl-11/milsap-full.html
(2898 words)
|
|
| |
| | Adis |
| | Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics | | | Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions. | | | Improving drug therapy through developments in pharmacokinetics and pharmacodynamics |
|
http://www.adis.com/page.asp?objectID=37
(301 words)
|
|
| |
| | Drug Interactions / Pharmacokinetics - HIV/AIDS News Stories |
| | Pharmacokinetics of Ziagen Are Not Affected by Viread | | | Pharmacokinetic Evaluation and Short-Term Activity of Stavudine, Nevirapine and Nelfinavir Therapy | | | Pharmacokinetic Interaction Between Rifabutin (RFB) and Fosamprenavir (FPV)/ Ritonavir (RTV) in Healthy Subjects, Y Chon and others. |
|
http://www.hivandhepatitis.com/recent/inter/interactions.html
(1160 words)
|
|
| |
| | British Journal of Pharmacology - Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular ... |
| | Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug | | | PRESANT C.A., WOLF W., WALUCH V., WISEMAN C., KENNEDY P., BLAYNEY D. and BRECHNER R.R. (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. | | | This study provides important insights into the integration of in vitro efficacy parameters, into the in vivo pharmacokinetic and pharmacodynamic evaluation of SQ109, and should facilitate future clinical trials of the compound. |
|
http://www.nature.com/bjp/journal/v144/n1/full/0705984a.html
(5763 words)
|
|
| |
| | Pharmacokinetics - Wikipedia, the free encyclopedia |
| | Disposition is further subdivided into the study of the distribution, metabolism and elimination or excretion of a drug. | | | By studying absorption -- the amount of a drug which gets into the system (bloodstream) following administration -- pharmacokinetics may guide the formulation of drug products. | | | Pharmacokinetics is a branch of pharmacology dedicated to the study of the time course of substances and their relationship with an organism or system. |
|
http://en.wikipedia.org/wiki/Pharmacokinetics
(788 words)
|
|
| |
| | IngentaConnect Clinical Pharmacokinetics of Cyclophosphamide |
| | Knowledge of the pharmacokinetics of cyclophosphamide, and possibly monitoring the pharmacokinetics of cyclophosphamide in individuals, may be useful for improving its therapeutic index. | | | Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug. | | | As these techniques are becoming increasingly available, adequate description of the pharmacokinetics of cyclophosphamide and its metabolites has become possible. |
|
http://www.ingentaconnect.com/content/adis/cpk/2005/00000044/00000011/art00003
(251 words)
|
|
| |
| | Basic Clinical Pharmacokinetics |
| | Basic Clinical Pharmacokinetics was designed to simplify pharmacokinetics to help busy practitioners understand and visualize basic principles. |
|
http://www.lww.com/product/0,0,0-7817-4147-5,00.html
(48 words)
|
|
| |
| | Zyban Pharmacology, Pharmacokinetics, Studies, Metabolism - Bupropion Hcl - RxList Monographs |
| | The pharmacologic activity and pharmacokinetics of the individual enantiomers have not been studied. | | | However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. | | | Hepatic: The effect of hepatic impairment on the pharmacokinetics of bupropion was characterized in 2 single-dose studies, one in patients with alcoholic liver disease and one in patients with mild to severe cirrhosis. |
|
http://www.rxlist.com/cgi/generic/buprop_cp.htm
(2268 words)
|
|
| |
| | Pharmacokinetics: and introduction |
| | Pharmacokinetics is the study of what the body does to a drug. | | | Pharmacodynamics is the study of what a drug does to the body. | | | It is essential that you understand each of the concepts discussed in this tutorial. |
|
http://www.4um.com/tutorial/science/pharmak.htm
(2122 words)
|
|
| |
| | pharmacokinetics - Hutchinson encyclopedia article about pharmacokinetics |
| | Clinical pharmacokinetics is the application of pharmacokinetic studies to clinical practice and to the safe and effective therapeutic management of the individual patient. | | | The effects and the duration of action of the drug are also taken into account. |
|
http://encyclopedia.farlex.com/pharmacokinetics
(107 words)
|
|
| |
| | PHARMACOKINETICS SOFTWARE CATALOGUE |
| | These techniques are particularly useful where the data are population pharmacokinetic data and when there are few measurements from each subject and/or the variation between subjects is considerable. | | | Workshops to compliment pharmacokinetics undergraduate course self assesment style. | | | Computer simulation of pharmacokinetics which enables patient factors and drug factors to be changed. |
|
http://www.chem.ac.ru/Chemistry/Soft/PHARMACO.en.html
(332 words)
|
|
| |
| | Amazon.com: Pharmacokinetics and Metabolism in Drug Design (Methods & Principles in Medicinal Chemistry): Books: Dennis ... |
| | Particular emphasis is placed on the impact of pharmacokinetic parameters on the discovery of new drugs - one of the most challenging tasks in global pharmaceutical research. | | | Van de Waterbeemd, Drug Metab, New York, Activity Relat, Drug Discov, Drug Research, Eds Testa, Pharmacokinetic Optimization, Plenum Press, Drug Dispos, Eds Borchardt, Eds Pliska, Raevsky H-bond | | | Clinical Pharmacokinetics: Concepts and Applications by Malcolm Rowland |
|
http://www.amazon.com/exec/obidos/tg/detail/-/3527301976?v=glance
(900 words)
|
|
| |
| | Digoxin Kinetics calculator. (Pharmacokinetics). Program by D.McAuley |
| | Mooradian AD: Digitalis: An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. | | | Koda-Kimble MA: Congestive heart failure, in Applied Therapeutics for Clinical Pharmacists, 2nd ed, edited by Koda-Kimble et al, Applied Therapeutics, Inc., San Francisco 1978; pp 161-86. | | | Aronson JK: Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. |
|
http://www.globalrph.com/digoxinsub.htm
(267 words)
|
|
| |
| | THE MERCK MANUAL, Sec. 22, Ch. 299, Pharmacokinetics |
| | An appropriate response to a drug requires the appropriate concentration of drug at the site of action. | | | This approach requires knowledge of the drug's pharmacokinetics as a function of the patient's age and weight and the kinetic consequences of concurrent diseases (eg, renal, hepatic, or cardiovascular disease or a combination of diseases). | | | Pharmacokinetics: Study of the time course of a drug and its metabolites in the body after administration by any route. |
|
http://www.merck.com/mrkshared/mmanual/section22/chapter299/299a.jsp
(188 words)
|
|
| |
| | CDC - Influenza (Flu) Pharmacokinetics |
| | In a single-dose study of patients with anuric renal failure, the apparent clearance of rimantadine was approximately 40% lower, and the elimination half-life was approximately 1.6-fold greater than that among healthy persons of the same age. | | | Further studies are needed to determine multiple-dose pharmacokinetics and the most appropriate dosages for patients with renal insufficiency. | | | In a study of persons with chronic liver disease (the majority with stabilized cirrhosis), no alterations in liver function were observed after a single dose. |
|
http://www.cdc.gov/flu/professionals/treatment/pharmacokinetics.htm
(445 words)
|
|
| |
| | Pharmacokinetics of Metronidazole in the Yellow Rat Snake, Elaphe obsoleta quadrivitatta |
| | This study examined pharmacokinetics of metronidazole, a drug used to treat anerobic infections, in wild-caught, yellow rat snakes, Elaphe obsoleta quadrivitatta. | | | A preliminary trial evaluated 20 mg/kg and 100 mg/kg doses, each dose given orally to two rat snakes. | | | Pharmacokinetics of Metronidazole in the Yellow Rat Snake, Elaphe obsoleta quadrivitatta |
|
http://www.arav.org/Journals/JA017736.htm
(397 words)
|
|
| |
| | Pharmacokinetics |
| | Estimating clinically significant organ functional changes and resultant pharmacokinetic consequences will lead to the design and development of effective pharmacologic countermeasures and therapeutic adjustments. | | | This effect will be compounded by anticipated changes in the hepatic metabolism of drugs and other xenobiotics. | | | Determine changes in the GI function and physiology. |
|
http://hrf.jsc.nasa.gov/science/pharmacokinetics.asp
(396 words)
|
|
| |
| | Pharmacokinetics objectives |
| | For IV anesthetic drug pharmacokinetics, special problems exist because those significant differences in individual drug requirements (up to 2-5 times) as a result of dose-plasma and plasma-effect relationships | | | Stoelting, R.K., "Pharmacokinetics and Pharmacodynamics of Injected and Inhaled Drugs", in Pharmacology and Physiology in Anesthetic Practice, Lippincott-Raven Publishers, 1999, 1-17. | | | By contrast to the above special problems associated with IV anesthetic drug pharmacokinetics and variation between drugs, a similar problem does not exist for the volatile agents were drug-effect relationships appear more predictable. |
|
http://www.pharmacology2000.com/General/Pharmacokinetics/kinobj1.htm
(4191 words)
|
|
| |
| | Laboratory of Applied Pharmacokinetics: About LAPK |
| | The Laboratory of Applied Pharmacokinetics (LAPK) of the School of Medicine at the University of Southern California is a resource for optimal study and control of pharmacokinetic systems and for individualized drug therapy supported in part by the National Library of Medicine (NLM) and National Center for Research Resources (NCRR). | | | Dissemination of the concepts and capabilities of this laboratory to other research institutions and to industry is carried out through workshops, short courses, technical reports, symposia, fellowships, and scientist-in-residence programs. | | | © 2000 - 2006 Laboratory of Applied Pharmacokinetics. |
|
http://www.lapk.org
(175 words)
|
|
| |
| | Pharmacokinetics for Pharmaceutical Scientists |
| | The course will emphasize basic principles in pharmacokinetics. | | | The course will highlight classic examples that demonstrate the effects of genetic polymorphisms on drug pharmacokinetics and pharmacodynamics. | | | The first three and one-half days of this limited enrollment course will be devoted to essential pharmacokinetic parameters and how they are employed to summarize and predict temporal relationships. |
|
http://www.ucsf.edu/dbps/events/pharmacokinetics2005.html
(428 words)
|
|
| |
| | PK Solutions Pharmacokinetics Software at SummitPK.com - List of Equations |
| | Malcolm Roland and Thomas N. Tozer, Clinical Pharmacokinetics - Concepts and Applications, Second edition (Lea and Febiger, Malvern, PA), 1989. | | | PK Solutions 2 User Guide, and describes the equations used by the software. | | | This document is taken from the pharmacokinetics equation section of the |
|
http://www.summitpk.com/equations/equations.htm
(1028 words)
|
|
| |
| | Pharmacokinetics and Biopharmaceutics , The University of Iowa |
| | Expanded Answers for problems in Rowland and Tozer's Clinical Pharmacokinetics: Concepts and Applications, 3rd edition. | | | Reading Assignments from Rowland and Tozer's Clinical Pharmacokinetics: Concepts and Applications, 3rd edition and Washington, Washington, and Wilson's Physiological Pharmaceutics: Barriers to Drug Absorption, 2nd edition.. | | | Pharmacokinetics and Biopharmaceutics (46:138) is a required course in the P-2 year of the Doctor of Pharmacy Program at The University of Iowa. |
|
http://www.uiowa.edu/~c046138/KINETICS_HOMEPAGE.htm
(217 words)
|
|
| |
| | Centre for Human Drug Research - CHDR.nl |
| | These can then be used to predict profiles under a variety of conditions (i.e. | | | Aspects of the course of drug concentrations may be described using pharmacokinetic parameters. | | | Click here for more information about CHDR publications including recent presentations. |
|
http://www.chdr.nl/?id=846
(185 words)
|
|
| |
| | Clinical Trial: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
| | The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE. | | | Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) | | | Clinical Trial: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
|
http://www.clinicaltrials.gov/ct/gui/show/NCT00113971?order=1
(369 words)
|
|
| |
| | Malaria - Artemether - Artenam |
| | Pharmacokinetics of oral ß-Artemether in healthy males and patients with acute, uncomplicated, falciparum malaria | | | Pharmacokinetics of oral B-Artemether in healthy males and patients with acute, uncomplicated, falciparum malaria | | | Artemisinin and related compounds are difficult to assay in body fluids. |
|
http://www.arenco.be/docu10.htm
(322 words)
|
|
| |
| | Pharmacokinetics |
| | Recommend when drug doses should be modified for patients with renal or hepatic dysfunction. | | | Identify when a patient would benefit from the determination of pharmacokinetic constants for the use of dosage adjustment using drug-specific techniques or Bayesian computer dosing programs. | | | Calculate a modified drug dosage regimen for an agent that follows linear pharmacokinetics given a steady-state drug concentration and current drug dose. |
|
http://highered.mcgraw-hill.com/sites/0071363610/student_view0/chapter4
(290 words)
|
|
| |
| | International Journal of Pharmaceutical Compounding: Pharmacokinetics in healthy volunteers of sumatriptan 25-mg oral ... |
| | Based upon its pharmacokinetic profile, the extemporaneous suppository may represent a useful alternative therapeutic administration route for some patients. | | | Sumatriptan was the first selective serotonin receptor agonist to be commercially available for the treatment of acute migraine headache.1 Its pharmacologic properties are well known and involve subpopulations of the serotonin (5-HT) receptors located in the cerebral and dural blood vessels. | | | Sixteen healthy volunteers enrolled in this open-label, two-way crossover study. |
|
http://www.findarticles.com/p/articles/mi_qa4101/is_200311/ai_n9326183
(491 words)
|
|
| |
| | Pharmacokinetics / Viral Kinetics |
| | Ribavirin Pharmacokinetics in Kidney and Liver Transplant Patients: Evidence That It Depends on Renal Function | | | Efficacy, Safety and Pharmacokinetics of NM283, a New Polymerase Inhibitor for the Treatment of Hepatitis C | | | Peginterferon alfa-2a (Pegasys) Does Not Alter the Pharmacokinetics of Methadone |
|
http://www.hivandhepatitis.com/hep_c/hepc_news_pharm.html
(136 words)
|
|
| |
| | Pharmacokinetic and Pharmacodynamic Resources |
| | "Pharmacokinetics is the study of the time course of drug and metabolite levels in different fluids, tissues, and excreta of the body, and of the mathematical relationships required to develop models to interpret such data." from Gibaldi, M. and Perrier, D. Pharmacokinetics, Marcel Dekker, page v. | | | To further the study of Pharmacokinetics and Pharmacodynamics I have set-up an e-mail list (LISTSERV) for people interested in discussing Pharmacokinetics and Pharmacodynamics with colleagues around the world. | | | The purpose of this page is to provide links to information about the discipline of Pharmacokinetics and Pharmacodynamics. |
|
http://www.boomer.org/pkin
(573 words)
|
|
| |
| | Clinical Trial: Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir |
| | Official Title: CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Verus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients | | | Further study details as provided by California Collaborative Treatment Group: | | | To evalute the relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) compared to the dual NRTI regimen of TDF+ABC as assessed by the short-term virologic response; 2. |
|
http://www.clinicaltrials.gov/ct/show/NCT00214890
(1042 words)
|
|
| |
| | Xanax Pharmacology, Pharmacokinetics, Studies, Metabolism - Alprazolam - RxList Monographs |
| | Using a specific assay methodology, the mean plasma elimination half-life of alprazolam has been found to be about 11.2 hours (range: 6.3-26.9 hours) in healthy adults. | | | Xanax Pharmacology, Pharmacokinetics, Studies, Metabolism - Alprazolam - RxList Monographs | | | These lesions did not appear until after 11 months of treatment. |
|
http://www.rxlist.com/cgi/generic/alpraz_cp.htm
(697 words)
|
|
| |
| | News - Losartan Does Not Alter Phenytoin's Pharmacokinetics |
| | Volunteers received each drug for 10 days with a three-week washout between. | | | Phenytoin shows a narrow therapeutic index and non-linear pharmacokinetics. | | | Losartan does not alter phenytoin's pharmacokinetics, however, phenytoin does inhibit the conversion of losartan to its active metabolite. |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C39001C43A7
(365 words)
|
|
| |
| | Regsource Pharmacokinetics |
| | Draft Guidance for Industry on Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling; Availability". |
|
http://www.regsource.com/Regs_Laws___Forms/Federal_Reg_1999/Pharmacokinetics/body_pharmacokinetics.html
(23 words)
|
|
| |
| | Pharmacokinetics Software for Research and Education at SummitPK.com |
| | Pharmacokinetics Software for Research and Education at SummitPK.com | | | Boston Univ. Medical School - Glossary of terms and symbols used in phramacology (and pharmacokinetics!) | | | A First Course in Pharmacokinetics and Biopharmaceutics - Dr. David W. Bourne |
|
http://www.summitpk.com/links/links.htm
(906 words)
|
|
| |
| | eBay - Book: Applied Biopharmaceuticals Pharmacokinetics (ISBN: 0071375503) |
| | Applied Biopharmaceuticals & Pharmacokinetics by Andrew B.C. Yu, Leon Shargel, Ronkonkoma Ny, Susanna Wu-Pong (2004) | | | Average rating: Be the first to review it! | | | eBay - Book: Applied Biopharmaceuticals Pharmacokinetics (ISBN: 0071375503) |
|
http://product.ebay.com/Applied-Biopharmaceuticals-Pharmacokinetics_ISBN_0071375503_W0QQfvcsZ1392QQsoprZ30445008
(223 words)
|
|
| |
| | Population Pharmacokinetics |
| | Evaluation of Population Fisher Information Matrix - S-PLUS functions to compute the population Fisher information matrix for the evaluation of population pharmacokinetic designs by S. Retout, et al. | | | You can read in NONMEM output and generate a range of diagnostic plots and carry out useful analysis, including GAM, bootstrap of the GAM, tree regression, and more. |
|
http://www.pharmastatsci.com/pharmacokinetics.htm
(155 words)
|
|
|
